Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy
LMY-920
Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome
https://www.einnews.com/pr_news/521168729/luminary-therapeutics-and-case-western-reserve-university-enter-formal-collaboration-for-development-of-baff-car
Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs.
The BAFF target was discovered by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.
Luminary intends to conduct IND-enabling non-clinical studies to support two clinical trials with its novel and proprietary non-viral autologous BAFF CAR-T (LMY-920) to treat Mantle Cell Lymphoma and Sjogren’s Syndrome. This BAFF target is unique in that it binds to three distinct receptors (BAFF, BCMA, and TACI). Additionally, this BAFF target avoids early B-Cells while targeting more mature B-Cells that express one of three antigens.
